A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Crossover Study to Evaluate the Efficacy and Safety of Lorundrostat in Participants With Moderate to Severe Obstructive Sleep Apnea and Hypertension
Sponsor: Mineralys Therapeutics Inc.
This PHASE2 trial investigates Hypertension and Obstructive Sleep Apnea and is currently completed. Mineralys Therapeutics Inc. leads this study, which shows 6 recorded versions since 2025 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Nov 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Feb 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mineralys Therapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .